1ST Biotherapeutics, Inc. announced a Clinical Trial Collaboration and Supply Agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.
September 19, 2023
· 2 min read
